Day-one subcutaneous Leqembi lets eligible early Alzheimer's patients start treatment with weekly shots instead of IV infusions. Family caregivers still carry the same core safety job: watch for brain swelling or bleeding symptoms and keep MRI checks on schedule. Leqembi Iqlik is subcutaneous lecanemab-irmb, an anti-amyloid drug that targets amyloid plaques in the brain.
According to the U.S. Food and Drug Administration in the FDA approval notice, approval came July 13, 2026 as a once-weekly initiation dose for early Alzheimer's. It is the first anti-amyloid therapy usable under the skin for the full starting course.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who can start it on day one?
- How do the home shots work?
- What is ARIA and when is risk highest?
- What monitoring still applies with shots?
- Which symptoms need a prompt call?
Who can start it on day one?
Treatment is for adults with mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid pathology. That group matches the population studied in the IV trials. A diagnosis of moderate or later dementia does not qualify.
Amyloid confirmation comes before the first shot. Ask the clinic what test result is on file and keep a copy. Do not start based on memory symptoms alone.
How do the home shots work?
According to Eisai and Biogen in the company approval statement, the initiation dose is 500 mg weekly as two back-to-back 250-mg autoinjector shots of about 15 seconds each. After 18 months, patients may switch to 360 mg weekly maintenance. Mark the two-shot routine on a weekly checklist so no second injector is missed.
Home use is not automatic on day one. Patients or caregivers may give shots at home only after a clinician directly supervises at least two consecutive doses and confirms home use fits. Use those supervised visits to practice skin site choice, timing, storage, and missed-dose rules.
What is ARIA and when is risk highest?
Leqembi carries an FDA boxed warning for amyloid-related imaging abnormalities, called ARIA. ARIA-E is temporary brain swelling. ARIA-H is small bleeds or iron deposits from bleeds.
Risk is usually highest in the first 14 weeks and first seven doses. That early window is when caregivers should be most alert. It does not mean later doses are risk-free.
What monitoring still applies with shots?
According to Medscape in its home-lecanemab care summary, labeling still requires a baseline brain MRI plus surveillance MRIs after about 1, 2, 3 and 6 months, whether drug is given by IV or shot. Shots remove infusions, not scans. Book the baseline and early scans before routines slip.
Genetic risk testing should come before treatment. According to Eisai in its ARIA risk summary, ApoE e4 homozygotes had about 45% ARIA on drug, compared with 19% in heterozygotes and 13% in noncarriers. Treatment remains allowed without testing, but risk cannot be stratified.
Which symptoms need a prompt call?
Call for evaluation right away for these changes: Expect mostly mild shot-site effects instead, such as pain, redness, or swelling in about 11% of subcutaneous users. Log the date, dose number, symptom, and time called, then bring the log to each visit.
- new or worse headache, confusion, or dizziness
- visual changes, nausea, or seizure
- gait trouble, weakness, or speech problems
You Might Also Like
- The House Passage of the AADAPT Dementia Training Act in 2026: What the Update Means for Family Caregivers
- CMS GUIDE 24-Hour Dementia Support in 2026: What the Update Means for Family Caregivers
- The Long-Term Care Data Cooperative and Dementia Research in 2026: Research Participation Questions for People With Mild Cognitive Impairment
